Research ExplorerPublicationsThe light and the dark sides of Interleukin-10 in immune-med...

The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer

Standard

The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. / Geginat, Jens; Larghi, Paola; Paroni, Moira; Nizzoli, Giulia; Penatti, Alessandra; Pagani, Massimiliano; Gagliani, Nicola; Meroni, Pierluigi; Abrignani, Sergio; Flavell, Richard A.

In: CYTOKINE GROWTH F R, Vol. 30, 08.2016, p. 87-93.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Geginat, J, Larghi, P, Paroni, M, Nizzoli, G, Penatti, A, Pagani, M, Gagliani, N, Meroni, P, Abrignani, S & Flavell, RA 2016, 'The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer', CYTOKINE GROWTH F R, vol. 30, pp. 87-93. https://doi.org/10.1016/j.cytogfr.2016.02.003

APA

Geginat, J., Larghi, P., Paroni, M., Nizzoli, G., Penatti, A., Pagani, M., Gagliani, N., Meroni, P., Abrignani, S., & Flavell, R. A. (2016). The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. CYTOKINE GROWTH F R, 30, 87-93. https://doi.org/10.1016/j.cytogfr.2016.02.003

Vancouver

Geginat J, Larghi P, Paroni M, Nizzoli G, Penatti A, Pagani M et al. The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer. CYTOKINE GROWTH F R. 2016 Aug;30:87-93. https://doi.org/10.1016/j.cytogfr.2016.02.003

Bibtex

@article{aa190d5acaac46aa9363bb67ffd03937,
title = "The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer",
abstract = "Interleukin-10 (IL-10) is known to be a tolerogenic cytokine since it inhibits pro-inflammatory cytokine production and T cell stimulatory capacities of myeloid cells, such as macrophages and dendritic cells. In particular, it has a non-redundant tolerogenic role in intestinal immune homeostasis, since mice and patients with genetic defects in the IL-10/IL-10R pathway develop spontaneously colitis in the presence of a normal intestinal flora. However, IL-10 is also a growth and differentiation factor for B-cells, can promote autoantibody production and has consequently a pathogenic role in systemic lupus erythematosus. Moreover, IL-10 can promote cytotoxic T-cell (CTL) responses and this immunogenic activity might be relevant in type-1 diabetes and anti-tumor immune responses. This review summarizes these paradoxic effects of IL-10 on different types of immune responses, and proposes that different cellular sources of IL-10, in particular IL-10-secreting helper and regulatory T-cells, have different effects on B-cell and CTL responses. Based on this concept we discuss the rationales for targeting the IL-10 pathway in immune-mediated diseases and cancer.",
keywords = "Journal Article",
author = "Jens Geginat and Paola Larghi and Moira Paroni and Giulia Nizzoli and Alessandra Penatti and Massimiliano Pagani and Nicola Gagliani and Pierluigi Meroni and Sergio Abrignani and Flavell, {Richard A}",
note = "Copyright {\textcopyright} 2016 Elsevier Ltd. All rights reserved.",
year = "2016",
month = aug,
doi = "10.1016/j.cytogfr.2016.02.003",
language = "English",
volume = "30",
pages = "87--93",
journal = "CYTOKINE GROWTH F R",
issn = "1359-6101",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer

AU - Geginat, Jens

AU - Larghi, Paola

AU - Paroni, Moira

AU - Nizzoli, Giulia

AU - Penatti, Alessandra

AU - Pagani, Massimiliano

AU - Gagliani, Nicola

AU - Meroni, Pierluigi

AU - Abrignani, Sergio

AU - Flavell, Richard A

N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.

PY - 2016/8

Y1 - 2016/8

N2 - Interleukin-10 (IL-10) is known to be a tolerogenic cytokine since it inhibits pro-inflammatory cytokine production and T cell stimulatory capacities of myeloid cells, such as macrophages and dendritic cells. In particular, it has a non-redundant tolerogenic role in intestinal immune homeostasis, since mice and patients with genetic defects in the IL-10/IL-10R pathway develop spontaneously colitis in the presence of a normal intestinal flora. However, IL-10 is also a growth and differentiation factor for B-cells, can promote autoantibody production and has consequently a pathogenic role in systemic lupus erythematosus. Moreover, IL-10 can promote cytotoxic T-cell (CTL) responses and this immunogenic activity might be relevant in type-1 diabetes and anti-tumor immune responses. This review summarizes these paradoxic effects of IL-10 on different types of immune responses, and proposes that different cellular sources of IL-10, in particular IL-10-secreting helper and regulatory T-cells, have different effects on B-cell and CTL responses. Based on this concept we discuss the rationales for targeting the IL-10 pathway in immune-mediated diseases and cancer.

AB - Interleukin-10 (IL-10) is known to be a tolerogenic cytokine since it inhibits pro-inflammatory cytokine production and T cell stimulatory capacities of myeloid cells, such as macrophages and dendritic cells. In particular, it has a non-redundant tolerogenic role in intestinal immune homeostasis, since mice and patients with genetic defects in the IL-10/IL-10R pathway develop spontaneously colitis in the presence of a normal intestinal flora. However, IL-10 is also a growth and differentiation factor for B-cells, can promote autoantibody production and has consequently a pathogenic role in systemic lupus erythematosus. Moreover, IL-10 can promote cytotoxic T-cell (CTL) responses and this immunogenic activity might be relevant in type-1 diabetes and anti-tumor immune responses. This review summarizes these paradoxic effects of IL-10 on different types of immune responses, and proposes that different cellular sources of IL-10, in particular IL-10-secreting helper and regulatory T-cells, have different effects on B-cell and CTL responses. Based on this concept we discuss the rationales for targeting the IL-10 pathway in immune-mediated diseases and cancer.

KW - Journal Article

U2 - 10.1016/j.cytogfr.2016.02.003

DO - 10.1016/j.cytogfr.2016.02.003

M3 - SCORING: Journal article

C2 - 26980675

VL - 30

SP - 87

EP - 93

JO - CYTOKINE GROWTH F R

JF - CYTOKINE GROWTH F R

SN - 1359-6101

ER -